Abstract
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Discovery and saturation analysis of cancer genes across 21 tumour types
10.1038/nature12912 · 2014
10.1038/nature12477
10.1038/nature12477
10.1182/blood-2010-04-279083
10.1182/blood-2010-04-279083
Characterization of aberrant pathways across human cancers
10.1186/1752-0509-7-s1-s1 · 2013
Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk
10.1177/1947601913503341 · 2013
10.1177/1947601913507951
10.1177/1947601913507951
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
2013
DNA sequencing of cancer: what have we learned?
10.1146/annurev-med-060712-200152 · 2013
Sequencing quality assessment tools to enable data-driven informatics for high throughput genomics
10.3389/fgene.2013.00288 · 2013
A review of post-GWAS prioritization approaches
2013
Emerging paradigms in genomics-based crop improvements
10.1155/2013/585467 · 2013
10.1038/nbt.2203
10.1038/nbt.2203
10.1158/2159-8290.cd-11-0110
10.1158/2159-8290.cd-11-0110
10.1158/2159-8290.cd-11-0184
10.1158/2159-8290.cd-11-0184
10.1038/nature07423
10.1038/nature07423
10.1177/1947601913486349
10.1177/1947601913486349
c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade
10.1177/1947601913485413 · 2013
JAK–STAT pathway and myogenic differentiation
2013
10.18632/oncotarget.1548
10.18632/oncotarget.1548
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
10.1182/blood-2012-07-446286 · 2013
10.1124/jpet.105.084145
10.1124/jpet.105.084145
Tyrosine kinase inhibitors — a review on pharmacology, metabolism and side effects
10.2174/138920009788897975 · 2009
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
10.1056/nejm200104053441402 · 2001
10.1038/nrc2106
10.1038/nrc2106
10.1056/nejmra1010600
10.1056/nejmra1010600
10.1056/nejmra1010517
10.1056/nejmra1010517
Drug-diagnostics co-development in oncology
10.3389/fonc.2013.00315 · 2013
New challenges and inspired answers for anticancer drug discovery and development
10.1093/jjco/hyt131 · 2013
Meeting the technical challenges of personalized medicine and companion diagnostics
2012
Biomarkers for determining the prognosis in chronic myelogenous leukemia
10.1186/1756-8722-6-54 · 2013
Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib
2013
10.1172/jci67509
10.1172/jci67509
Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?
10.7150/thno.7445 · 2013
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development
10.3389/fonc.2013.00313 · 2013
10.2217/nnm.13.3
10.2217/nnm.13.3
10.1002/jps.23773
10.1002/jps.23773
10.1016/j.ymeth.2013.01.007
10.1016/j.ymeth.2013.01.007
Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule
2014
10.1371/journal.pone.0007887
10.1371/journal.pone.0007887
10.1371/journal.pone.0024433
10.1371/journal.pone.0024433
10.1038/nrd892
10.1038/nrd892 · doi-reference
Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue
10.1517/17425247.5.4.459 · doi-reference
10.5487/tr.2012.28.4.217
10.5487/tr.2012.28.4.217 · doi-reference
Synthesis of surfactant free PCL–PEG brushed nanoparticles with tunable degradation kinetics
10.1016/j.ijpharm.2013.06.020 · doi-reference
10.1517/17425247.2010.538679
10.1517/17425247.2010.538679 · doi-reference
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles
10.1038/srep03313 · doi-reference
A review of mammalian toxicity of ZnO nanoparticles
10.2147/nsa.s23932 · doi-reference
Gold nanoparticles: recent aspects for human toxicology
10.1186/1745-6673-8-32 · doi-reference
10.2147/ijn.s596
10.2147/ijn.s596 · doi-reference
Integrated multiplatform method for in vitro quantitative assessment of cellular uptake for fluorescent polymer nanoparticles
10.1088/0957-4484/25/4/045102 · doi-reference
10.1163/156856207779996931
10.1163/156856207779996931 · doi-reference
10.1038/nnano.2012.168
10.1038/nnano.2012.168 · doi-reference
Multiple myeloma: destruction of Ikaros
10.1038/nrc3663 · doi-reference
Erdheim–Chester: beyond the lesion
10.1182/blood-2011-01-330233 · doi-reference
10.1016/s1470-2045(05)70388-0
10.1016/s1470-2045(05)70388-0 · doi-reference
High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses
10.1182/blood-2012-05-430140 · doi-reference
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives
10.2174/157015906776359568 · doi-reference
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management
10.1634/theoncologist.12-5-610 · doi-reference
Cancer. Cancer cell phenotypes, in fifty shades of grey
10.1126/science.1234415 · doi-reference
10.1007/bf02893361
10.1007/bf02893361 · doi-reference
10.1038/nature12213
10.1038/nature12213 · doi-reference
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
10.2217/pgs.12.102 · doi-reference
Pharmacogenetics of warfarin: challenges and opportunities
10.1038/jhg.2013.40 · doi-reference
Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients
10.1177/0300060513499094 · doi-reference
Practical guidance for implementing predictive biomarkers into early phase clinical studies
10.1155/2013/891391 · doi-reference
Oncogenes: direct hit on mutant RAS
10.1038/nrc3650 · doi-reference
10.1038/nrc3563
10.1038/nrc3563 · doi-reference
10.1038/nrc1434
10.1038/nrc1434 · doi-reference
10.4046/trd.2013.75.5.188
10.4046/trd.2013.75.5.188 · doi-reference
10.1038/nrc2559
10.1038/nrc2559 · doi-reference
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
10.1016/j.leukres.2013.09.011 · doi-reference
10.1038/nrc3612
10.1038/nrc3612 · doi-reference
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results
10.1159/000112795 · doi-reference
10.1016/j.jaad.2010.06.051
10.1016/j.jaad.2010.06.051 · doi-reference
10.2217/fon.13.62
10.2217/fon.13.62 · doi-reference
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
10.1038/nrc2152 · doi-reference
10.1053/j.seminhematol.2013.09.006
10.1053/j.seminhematol.2013.09.006 · doi-reference
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders
10.1056/nejmoa0804953 · doi-reference
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up
10.1007/s12185-013-1470-1 · doi-reference
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
10.1038/ng.375 · doi-reference